Table 1. Baseline Characteristics of Studies Included in the Network Meta-analysis of Patients With ES-SCLC.
| Source | Phase | Treatment | Participants, No. | ORR, No./total No. (%) | DCR | PFS, median, m | HR (95% CI) | P value | OS, median, m | HR (95% CI) | P value | TRAE 3-5, No./total No. (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paz-Ares et al,16 2019 | 3 | Durvalumab plus etoposide-platinum chemotherapy | 268 | 182/268 (67.9) | NR | 5.10 | 0.78 (0.65-0.94) | NR | 13.00 | 0.73 (0.59-0.91) | .005 | 163/265 (61.5) |
| Etoposide-platinum chemotherapy | 269 | 155/269 (57.6) | NR | 5.40 | 10.30 | 166/266 (62.4) | ||||||
| Kim et al,37 2019 | 3 | Irinotecan plus carboplatin | 173 | 108/173 (62.4) | 132/173 (76.3) | 6.50 | 0.846 (0.709-1.008) | .12 | 10.90 | 0.879 (0.73-1.05) | .12 | NR |
| Etoposide plus carboplatin | 189 | 91/189 (48.1) | 142/189 (75.1) | 5.80 | 10.30 | NR | ||||||
| Horn et al,17 2018 | 3 | Atezolizumab plus etoposide plus carboplatin | 201 | 121/201 (60.2) | 163/201 (81.1) | 5.20 | 0.77 (0.62-0.96) | .02 | 12.30 | 0.70 (0.54-0.91) | .007 | 115/198 (58.1) |
| Etoposide plus carboplatin | 202 | 130/202 (64.4) | 173/202 (85.6) | 4.30 | 10.30 | 113/196 (57.7) | ||||||
| Tiseo et al,12 2017 | 3 | Etoposide-platinum chemotherapy plus bevacizumab | 103 | 57/103 (55.3) | 73/103 (70.9) | 5.70 | 0.72 (0.54-0.97) | .03 | 8.90 | 0.78 (0.58-1.06) | .11 | 64/103 (62.1) |
| Etoposide plus platinum | 101 | 59/101 (58.4) | 68/101 (67.3) | 6.70 | 9.80 | 52/95 (54.7) | ||||||
| Reck et al,18 2016 | 3 | Ipilimumab plus etoposide-platinum chemotherapy | 566 | 297/478 (62.1) | 422/478 (88.3) | 4.60 | 0.85 (0.74-0.97) | .02 | 11.00 | 0.94 (0.81-1.09) | .38 | 231/478 (48.3) |
| Etoposide-platinum chemotherapy | 566 | 196/476 (41.2) | 422/476 (88.7) | 4.40 | 10.90 | 214/476 (45.0) | ||||||
| Shi et al,34 2015 | 2 | Irinotecan plus cisplatin | 30 | 21/30 (70.0) | 21/30 (70) | 6.00 | NR | NR | 18.10 | NR | NR | NR |
| Etoposide plus cisplatin | 32 | 21/32 (65.6) | 23/32 (71.9) | 6.00 | 15.10 | NR | ||||||
| Schmittel et al,39 2011 | 3 | Irinotecan plus carboplatin | 106 | 66/106 (62.3) | NR | 6.00 | 1.29 (0.96-1.73) | .07 | 10.00 | 1.34 (0.97-1.85) | .06 | NR |
| Etoposide plus carboplatin | 110 | 69/110 (62.7) | NR | 6.00 | 9.00 | NR | ||||||
| Spigel et al,11 2011 | 2 | Etoposide-platinum chemotherapy plus bevacizumab | 52 | 30/52 (57.7) | NR | 5.50 | 0.52 (0.32-0.83) | NR | 9.40 | 1.16 (0.66-2.04) | NR | 38/51 (74.5) |
| Etoposide-platinum chemotherapy | 50 | 24/50 (48.0) | NR | 4.40 | 10.50 | 28/47 (59.6) | ||||||
| Zatloukal et al,40 2010 | 3 | Irinotecan plus cisplatin | 202 | 79/202 (26.1) | 156/202 (77.2) | NR | NR | NR | 10.20 | 0.81 (0.65-1.01) | .06 | NR |
| Etoposide plus cisplatin | 203 | 94/203 (46.3) | 155/203 (76.4) | NR | 9.70 | NR | ||||||
| Lara et al,10 2009 | 3 | Irinotecan plus cisplatin | 324 | 194/324 (59.9) | NR | 5.80 | NR | .07 | 9.90 | NR | .71 | 213/317 (67.2) |
| Etoposide plus cisplatin | 327 | 186/327 (78.5) | NR | 5.20 | 9.10 | 274/324 (84.6) | ||||||
| Hermes et al,36 2008 | 3 | Irinotecan plus carboplatin | 105 | NR | NR | NR | NR | NR | 8.50 | 1.41 (1.06-1.87) | .02 | NR |
| Etoposide plus carboplatin | 104 | NR | NR | NR | 7.10 | NR | ||||||
| Hanna et al,35 2006 | 3 | Irinotecan plus cisplatin | 221 | 106/221 (48.0) | 115/221 (52) | 4.10 | NR | .37 | 9.30 | NR | .74 | NR |
| Etoposide plus cisplatin | 110 | 48/110 (43.6) | 56/110 (50.9) | 4.60 | 10.20 | NR | ||||||
| Schmittel et al,33 2006 | 2 | Irinotecan plus carboplatin | 35 | 22/35 (62.9) | 25/35 (71.4) | 9.00 | NR | .03 | NR | NR | NR | NR |
| Etoposide plus carboplatin | 35 | 20/35 (57.1) | 23/35 (65.7) | 6.00 | NR | NR | ||||||
| Noda et al,38 2002 | 3 | Irinotecan plus cisplatin | 77 | 65/77 (84.4) | NR NR |
6.90 | 0.61 (0.44-0.84) | .003 | 12.80 | NR | .002 | NR |
| Etoposide plus cisplatin | 77 | 52/77 (67.5) | 4.80 | 9.40 | NR |
Abbreviations: DCR, disease control rate; ES-SCLC, extensive-stage small cell lung cancer; HR, hazard ratio; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TRAE 3-5, treatment-related adverse event, grades 3 to 5.